womenzbiz.US Editorial Team

Networking in a Virtual World

The large, in-person networking event is actually off-putting these days, redefined by COVID-19, but networking is still an essential tool to build business and a career. Consider that 80% of all open positions aren’t advertised but instead found through personal connections! According to Korn Ferry, 85% of all positions are actually filled via networking.  Pandemic …

Networking in a Virtual World READ MORE

JOBS: Where are the Healthcare Jobs & How to Get Them

The Healthcare category has come into its own during the world’s two years of Covid- 19 focus. And it’s not just the nursing field that has exploded. To get an insight on the executive employment picture, we reached out to major search firms and healthcare leadership for the real picture of the industry’s employment needs …

JOBS: Where are the Healthcare Jobs & How to Get Them READ MORE

BrainScope and Aon Secure IP-based Funding Deal

Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. The funding arrangement provides BrainScope with up to $35 million in capital to fund the full expansion of its commercial activities as well as to develop new clinical applications on its platform. “More than four million …

BrainScope and Aon Secure IP-based Funding Deal READ MORE

A Pharma Powerhouse for Women – Organon – on Communicating About Healthcare

Organon “envisions a better and healthier every day for every woman” by focusing on medical issues and targeted solutions impacting women.  Today it’s a global healthcare company formed through a spinoff from Merck, and builds upon our strong foundation of more than 60 medicines and other products across a range of areas including reproductive health, …

A Pharma Powerhouse for Women – Organon – on Communicating About Healthcare READ MORE

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain High Risk Early Breast Cancer

Eli Lilly announced last month that the U.S. Food and Drug Administration (FDA) had approved its Verzenio (abemaciclib) for a specific type of early breast cancer that is at high risk of recurrence after surgery. The drug is limited to patients who test at least 20% for a Ki-67 score on an FDA-approved test. Ki-67 is a marker of cellular …

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain High Risk Early Breast Cancer READ MORE

Shopping Cart
Welcome to

We do what no one else does. We show the breadth and depth of remarkable women leaders. They are real women - with life stories to share - successes and failures, highs and lows. Their stories will empower more women to discover, accomplish and share their business dreams and goals.

In each issue we dive into a specific business segment. This issue focuses on Healthcare - certainly front and center in our lives. Future issues will focus on Finance, Marketing, Technology, Entrepreneurship ... Skills are transferable and there's so much to learn from the businesswomen in every issue.

HERE is a special welcome from our Founder.

Click HERE to go straight to the Website.

Scroll to Top